

Curriculum Vitae



Liang Han MD, Chief Doctor, Professor

Education & Training

- German Language Institute, Beijing Foreign Language University, 1991-1992
- Guest Doctor, Department of General Surgery, State Hospital St. Gallen, Switzerland, 1992-1994
- Visiting Fellow, MDC Molecular Medical Center, Roberet-roessle Clinic, Charite, Humboldt University of Berlin, Germany, 1999-2000
- Visiting Fellow, MD Anderson Cancer Center, Huston, Texas, USA, 2007
- MD, Medical Faculty, Tianjin Medical College, Tianjin 1980-1985

Current Positions

- Director of Gastrointestinal Oncological Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. Chief Doctor, Professor of Tianjin Medical University. 2004.

Previous Professional Experiences

- Director of Gastric Cancer Surgical Department, Tianjin Medical University Cancer Institute & Hospital, 2004-2016
- Deputy Director of Gastrointestinal Oncological Surgery, Tianjin Medical University Cancer Institute and Hospital, Chief Doctor, 2000-2004.
- Deputy-Chief Doctor, Department of Abdominal Oncology, Tianjin Medical University Cancer Institute and Hospital, 1995-2000.
- Resident, Department of Abdominal Oncology, Tianjin Cancer Hospital, 1985-1995

Board Certification

- Members of Board, Chinese Anti-Cancer Association, 1997,
- Members of Chinese Medical Association, 1990,
- Vice-President of Gastric Committee, Chinese Anti-Cancer Association, 2010,

- Vice-President of Gastric Cancer Committee, Chinese Medical Association,2013
- Vice-President of Surgical Oncologic Committee, Chinese Doctor's Association,2014
- Member of International Gastric Association

Recent key publications (2014-present)

1. Deng JY,Zhang RP, Pan Y, Wang BG, Wu LL, Jiao XG, Bao T, Hao XS, **Liang H**. Comparison of the staging of regional lymph nodes using the sixth and seventh editions of the TNM classification system for the evaluation of overall survival in gastric cancer patients: findings of a case-control analysis involving a single institute in China. *Surgery* 2014; 156(1):64-74
2. Deng JY, Zhang RP, **Liang H**, et al. Methylated CpG site count of dapper homolog 1 (DACT1) promoter prediction the poor survival of gastric cancer. *Am J Cancer Res* 2014;4(5):518-27
3. Deng JY, zhang R, Jiang N, **Liang H**, et al. Superior of the ratio between negative and positive LN for predicting the prognosis for patients with GC. *Ann Surg Oncol* 2014;DOI 10.1245/s10434-014-4128-8
4. Deng JY, Jiang N, Liu Hong G, **Liang H**. Clinical significance of the methylated cytosine-phosphate- guanine sites of protocadherin-10 promoter for evaluating the prognosis of gastric cancer. *J Am Coll Surg* 2014 Jun 26. Pii: S1072-7515(14)00502-X
5. Deng JY, Zhang RP, Pan Y, Ding XW, Cai MZ, Liu Y, Liu HG, Bao T, Jiao XG, Hao XS, **Liang H**. Tumor size as a recommendable variable for accuracy of the prognostic prediction of gastric cancer: a retrospective analysis of 1521 patients. *Ann Surg Oncol* 2014;Aug 26, doi:10.1245/s10434-014-4014-x
6. Deng JY, Liu H, Liang Y, **Liang H**, et al. Methylation of ras association domain protein 10 promoter negative association with the survival of gastric cancer. *Am J Cancer Res*2014;4(6):916-23
7. Jiang N, Deng JY, **Liang H**, et al. Node-extranodal soft tissue stage based on extranodal metastasis is associated with poor prognosis of patients with gastric cancer. *J Surg Res* 2014;192(1):90-7
8. Jiao XG, Deng JY, Wang XN, **Liang H**. Prognostic value of number of examined lymph nodes in patients with node-negative gastric cancer. *J Gastroenterol*. 2014 Apr 7;20(13):3640-8.
9. Liang Y, Deng JY, **Liang H**, et al. The positive impact of surgeon specialization on survival for gastric cancer patients with curative intent. *Gastric Cancer*. 2014 Oct 15. [Epub ahead of print]PMID:25315086

10. Jiang N, Deng J, **Liang H**, et al. Tumor volume as a prognostic factor was superior to the seventh edition of the pT classification in resectable gastric cancer. *Eur J Surg Oncol*. 2015;41(3):315-22.
11. Deng JY, Jiang N, Jiao XG, **Liang H**, et al. Tumor size as a recommendable variable for accuracy of the prognostic prediction of gastric cancer: A retrospective analysis of 1521 patients. *Ann Surg Oncol* 2015;22:565-572
12. Liu HG, Liu Y, Kong FM, Xin W, Li XJ, **Liang H**. Elevated levels of SMYD3 are correlated with over-expression of Transforming growth factor-beta1 in gastric cancer. *J Am Coll Surg* 2015 doi:10.1016/j.jamcollsurg.2015.02.023.
13. Deng J, Zhang R, Hou Y, Liu Y, Ying G, Pan Y, Hao X, **Liang H**. Clinical and experimental role of ring finger protein 180 on lymph node metastasis and survival gastric cancer. *Brit J Surg* 2016;103:407-416.
14. Deng JY, Yamashita H, Seto Y, **Liang H**. Increasing the number of examined lymph nodes is a prerequisite for improvement in the accurate evaluation of overall survival of node-negative gastric cancer patients. *Ann Surg Oncol* 2016;Oct 21doi:10.1245/s10434-016-5513-8
15. **Liang H**, Deng JY. Evaluation of rational extent lymphadenectomy for local advanced gastric cancer. *Chin J Cancer Res* 2016;28(4):397-403
16. Yamashita H, Deng J, **Liang H**, et al. Re-evaluating the prognostic validity of the negative to positive lymph node ratio in node-positive gastric cancer patients. *Surgery* 2016 doi: 10.1016/j.surg.2016.12.018.